Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma

Next Previous
Trial Profile

A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Avelumab (Primary) ; Trabectedin (Primary)
  • Indications Leiomyosarcoma; Liposarcoma
  • Focus Adverse reactions

    • Most Recent Events

    • 14 Jun 2018 Planned primary completion date changed from 15 Oct 2018 to 15 Apr 2019.
    • 28 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 08 Sep 2017 Planned End Date changed from 15 Mar 2020 to 15 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top